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Abstract 
Drug-induced gingival enlargement (DIGE) is a fibrotic condition associated with systemic 
administration of the anti-epileptic drug, phenytoin. We have previously demonstrated that 
periostin, which is transforming growth factor-beta (TGF-β) inducible gene, is upregulated in 
various fibrotic conditions including gingival enlargement associated with nifedipine. The 
objective of this study was to assess periostin expression in phenytoin-induced gingival 
enlargement (PIGE) tissues and to investigate the mechanisms underlying periostin expression. 
Human PIGE tissues were assessed using Masson’s trichrome, with cell infiltration and changes 
in extracellular matrix composition characterized through labeling with antibodies to periostin, 
phospho-SMAD 3, TGF-β, as well as the macrophage markers CD68 and RM3/1. Using human 
gingival fibroblasts (HGFs) in vitro, we examined the pathways through which phenytoin acts on 
fibroblasts. In PIGE tissues, which demonstrate altered collagen organization and increased 
inflammatory cell infiltration, periostin protein was increased compared with healthy tissues. p-
SMAD2/3, the transcription factor associated with canonical TGF-β signaling, is localized to the 
nuclei in both gingival fibroblasts and oral epithelial cells in PIGE tissues, but not in healthy 
tissue. In vitro culture of HGFs with 15 and 30 µg/ml of phenytoin increased periostin protein 
levels, which correlated with p-SMAD3 phosphorylation. Inhibition of canonical TGF-β 
signaling with SB431542 significantly reduced phenytoin induction of SMAD3 phosphorylation 
and periostin expression in HGFs. Analysis of PIGE tissues showed a subset of CD68 stained 
macrophages were TGF-β positive and that RM1/3 regenerative macrophages were present in the 
tissues. Our results demonstrate that phenytoin up-regulates periostin in HGFs in a TGF-
β−dependent manner. 
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Introduction 
Drug-induced gingival enlargement (DIGE) is a pathological condition that can develop 
due to the systemic administration of the anti-seizure drug phenytoin. DIGE is often evident 
within 1 month of the onset of the drug regimen (Brew et al., 2000; Kaur et al., 2010). DIGE can 
cause severe problems with regards to speech, breathing, eating, and can cause malocclusion in 
the jaw. Of great clinical concern, DIGE also increases the oral bacterial load by generating 
plaque retention sites surrounding the tissue that cannot be removed/accessed by brushing. DIGE 
was classified by the American Academy of Periodontology as a plaque- mediated condition 
(Armitage., 1999), with current evidence suggesting that DIGE is a fibrotic lesion (Brown et al., 
1991; Dill and Iacopino., 1997; Steinsvoll et al., 1999; Kataoka et al., 2000; Uzel et al., 2001).   
Histologically, DIGE is characterized by the presence of an irregular and thickened 
epithelium, elongated rete ridges, and increased deposition of fibrous connective tissue 
(Heasman and Hughes, 2014). The large epithelial ridges protrude deep into the underlying 
connective tissue (van der Wall et al., 1985; Nery et al., 1995). In the connective tissue, 
increased proliferation of fibroblasts coupled with diminished apoptosis is evident, as well as 
excess production of ECM. The excess ECM is characterized by increased bundles of irregular 
collagen (Heasman and Hughes., 2014) as well as an increase in glycosaminoglycan content 
(Mariani et al., 1996).  
Another major hallmark of DIGE is extensive infiltration of inflammatory cells, including 
macrophages, monocytes, and lymphocytes (Heasman and Hughes., 2014). The degree of 
inflammation in the connective tissue varies depending on the drug underlying the condition, 
with phenytoin induced enlargement considered the most fibrotic with the least inflammation 
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(Trackman and Kantarci., 2015). However, phenytoin-induced gingival enlargement (PIGE) is 
still characterized by an extensive infiltration of macrophages, plasma cells, and lymphocytes 
(Heasman and Hughes., 2014). An increased number of regenerative macrophages were evident 
in DIGE tissues compared to inflamed tissues from subjects not treated with phenytoin (Iacopino 
et al.. 1997). RM3/1, a marker associated with an regenerative macrophage phenotype, was 
higher in PIGE tissues compared to tissues from subjects not treated with phenytoin. 
Regenerative macrophages are associated with production of growth factors such as transforming 
growth factor-beta 1 (TGF-beta1), whereas inflammatory macrophages produce pro-
inflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha1) (Zwadlo et al., 1985; 
Zwadlo et al., 1986; Noble et al., 1993).  
Many proteins that have been identified to contribute to fibrosis are activated in response 
to TGF-β, including matricellular proteins that modulate cell-matrix interactions (Bornstein and 
Sage., 2002). Matricellular proteins, other than connective tissue growth factor (CCN2), have not 
been investigated in the context of DIGE (Uzel et al., 2001). Periostin, a recently classified 
matricellular protein (Norris et al., 2008a), is associated with collagen-rich tissues where it 
regulates functional and structural properties of connective tissues (Hamilton., 2008). In recent 
years, increased periostin expression levels have been strongly correlated with several fibrotic 
conditions and regenerative responses (Elliott and Hamilton., 2011). However, the expression of 
periostin in PIGE has never been investigated.  
Whether phenytoin directly induces gingival enlargement is still unclear and based on the 
literature, controversial, since other contributing factors such as gender, drug dose, and duration 
have yet to be fully eliminated. In this study, we assessed whether periostin is associated with 
PIGE and the mechanism of action of phenytoin on gingival cells and tissues.  
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Materials and Methods 
Tissue Preparation and Immunohistochemistry 
Clinically healthy gingiva was obtained with informed consent from six patients undergoing 
periodontal or implant therapies at the Oral Surgery Clinic at The University of Western Ontario. 
The use of all tissue material was in accordance with the guidelines of the University’s Research 
Ethics Board for Health Sciences Research involving Human Subjects (HSREB  requiring 
informed consent. Tissues were fixed in 10% neutral buffered formalin (Sigma Aldrich; St. 
Louis, MO, USA, paraffin embedded, and 5 µm sections cut. Formalin fixed gingival tissues 
from eleven patients with PIGE were obtained from the oral pathology laboratory. The patient 
demographics is shown in table 1. Immunohistochemistry was performed as previously described 
(Wen et al., 2010; Zhou et al., 2010; Elliott et al., 2012). In brief, tissues were deparaffinized and 
immune-labeled using primary antibodies against periostin (sc49480; Santa Cruz Biotechnology; 
Dallas, TX, USA; 1:100), alpha-smooth muscle actin (α-SMA) (ab5694; Abcam; Cambridge, 
MA, USA; 1:400), RM3/1 (ab17051; Abcam) and phosphorylated-SMAD2/3 (p-SMAD2/3) (Ser 
423/425) (sc-11769; Santa Cruz Biotechnology; Dallas, TX, USA; 1:100). Primary antibodies 
were detected using the ImmPRESS Reagent Kit Peroxidase (Vector Laboratory; Burlingame, 
CA, USA) and DAB reagent (Vector Laboratory) following the manufacturer’s instructions. 
Tissue sections omitting the primary antibody were used as a negative experimental control. All 
sections were counterstained with haematoxylin (Sigma Aldrich). To assess collagen density and 
arrangement in tissues, deparaffinized histological sections were stained using a Masson’s 
trichrome stain (University Hospital, London, ON, Canada). Images of tissues stained with 
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Masson’s trichrome were taken on a DM1000 light microscope (Leica; Concord, Ontario, 
Canada) and Leica Application Suite Software (version 3.8).  
 
Immunofluorescence 
Deparaffinized sections were also fluorescently stained. Tissues were permeabilized with 0.1% 
Triton X-100 (Caledon; Georgetown, ON, Canada) PBS, blocked with 10% horse serum in 0.1% 
Triton X-100 PBS, and incubated with CD68 (ab955; Abcam; Cambridge, MA, USA; 1:100), 
TGF-β (R&D Systems; Minneapolis, MN, USA; 1:100), and TNF-α (ab6671; Abcam; 1:100) 
primary antibodies overnight. CD68 was detected using Cy5-conjugated anti-mouse secondary 
antibodies (Molecular Probes; Carlsbad, CA, USA). TGF-β primary antibody was detected using 
FITC-conjugated anti-rabbit secondary antibody (Molecular Probes). All sections were 
counterstained with Hoechst 3342 dye (1:5000) for nuclei. Images were taken on Carl Zeiss 
Imager M2m microscope (Carl Zeiss; Jena, Germany) using Zen Pro 2012 software. 	
Human Gingival Fibroblast Isolation 
Clinically healthy gingiva was obtained from 6 patients undergoing crown lengthening or 
implant therapies at the Oral Surgery Clinic at The University of Western Ontario under 
informed consent. The use of all tissue material was in accordance with the guidelines of the 
University’s Research Ethics Board for Health Sciences Research involving Human Subjects 
(HSREB) requiring informed consent. Healthy HGFs were obtained from tissue from individuals 
who have no history of the drug therapy using explant cultures (Brunette et al., 1983). HGFs 
were maintained in high glucose Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen; 
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Carlsbad, CA, 
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USA) and 1X antibiotics and antimycotics (AA; 100 μg/ml penicillin G, 50 μg/ml gentamicin, 25 
μg/ml amphotericin B), in 75 cm2 tissue culture plastic flasks, at 37°C in a humidified 
atmosphere of 95% air 5% CO2. Cells were removed from the growth surface with trypsin 
[0.25% trypsin (Gibco), 0.1% glucose, citrate-saline buffer (pH 7.8)]. Cells between passage 2 
and 7 were used in experiments.  
 
Phenytoin treatment  
HGFs were seeded at a density of 60,000 cells per well. Prior to nifedipine treatment, HGFs were 
serum-starved in low-glucose DMEM overnight before treatments. For phenytoin treatment, 5,5-
Diphenylhydantoin (phenytoin) (D4007; Sigma Aldrich) was reconstituted in dimethyl sulfoxide 
(DMSO) (Sigma Aldrich) followed by dilution in low-glucose DMEM (0.5% FBS and 1% AA) 
at final concentrations of 15 and 30 µg/ml. HGFs were cultured in DMEM containing 15 µg/ml 
of phenytoin, or 30 µg/ml of phenytoin for 30 minutes, or 24 hours. HGFs treated with DMEM 
containing the equal volume of DMSO without phenytoin served as control to provide baseline. 	
To inhibit TGF-β signaling ALK5 (TGF- β receptor I), SB431542 (10 μM) (S4317; Sigma 
Aldrich) was used while the equal volume of DMSO solvent served as control. Parallel cultures 
of HGFs were pre-treated with low-glucose DMEM (0.5% FBS and 1% AA) containing ALK5 
inhibitor SB431542 at 10 μM or control DMSO 30 minutes prior to phenytoin treatment. 
Subsequently, HGFs were treated with DMEM containing DMSO alone, phenytoin (30 µg/ml), 
or both phenytoin (30 µg/ml) and SB431542 for 30 minutes,	and	24	hours.		
 
HI
ST
OL
OG
Y 
AN
D 
HI
ST
OP
AT
HO
LO
GY
 
(no
n-e
dit
ed
 m
an
us
cri
pt)
 
Western blot 
HGFs were washed twice with PBS and harvested with RIPA buffer (Sigma Aldrich) containing 
protease (Roche Diagnostics GmbH; Mannheim, Germany) and phosphatase inhibitor 
(Calbiocam; Billerica, MA, USA) cocktails. Cell lysates were sonicated and centrifuged at 
13,000 rpm for 20 minutes. Protein concentration was determined by Pierce® BCA Protein assay 
kit (Pierce; Waltham, MA, USA). 25 μg proteins of each sample were separated by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to 
nitrocellulose membranes. Membranes were washed with Tris-buffered saline containing 0.05% 
Tween-20 (TBS-T) and blocked with 5% dried milk in TBS-T. Primary antibodies for 
phosphorylated-SMAD3 (p-SMAD3) (ser423/425) (ab52903; Abcam), periostin (ab92460; 
Abcam), and GAPDH (Millipore; Billerica, MA, USA) were used. Detection was with 
appropriate perioxidase-conjugated secondary antibodies (Jackson ImmunoResearch; West 
Grove, PA, USA), which were developed with SuperSignal Western Pico Chemiluminescence 
Substrate (Pierce; Waltham, MA, USA).  
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Results 
Extracellular matrix organization is altered and periostin is increased in PIGE tissue  
To assess collagen organization and cell infiltration in healthy and DIGE human gingival 
samples, sections were stained using Masson’s trichrome. In comparison to healthy gingival 
tissues (n = 6), the collagen content was qualitatively higher in gingival tissues from patients 
diagnosed with PIGE (n = 11) (Figure 1). In all PIGE samples, epithelial hyperplasia was evident 
and increased inflammatory cell infiltrate in PIGE was noted compared to healthy gingiva, 
although the level of inflammatory cells observed varied between patients with PIGE (Figure 1). 
Gingival connective tissues in healthy gingiva had low immuno-reactivity for periostin, with the 
protein detectable only in the basement zone and superficial papillary lamina propria. (Figure 
2A). In contrast, an elevated level of periostin was observed i  the connective tissues of 
phenytoin-induced gingival enlargement compared to healthy tissue. In PIGE, periostin 
immunoreactivity localized to collagen fibrils in the gingival connective tissue (Figure 2A), but 
periostin was not associated with regions of inflammatory cells.  
 
Phenytoin increases periostin through TGF-β signaling in HGFs in vitro 
As we have shown in a previous paper (Kim et al., 2013) that nifedipine activates TGF-β 
signaling to increase periostin expression, we next assessed whether a similar mechanism would 
exist in HGFs in the presence of phenytoin. Using western blotting, periostin protein level was 
assessed in cell lysates. Periostin protein increased in HGFs treated with phenytoin at either 15 or 
30 µg/ml compared to control cells, at 24 h post-treatment (Figure 2B). We next assessed 
whether phenytoin increases periostin through TGF-β signaling. Untreated HGFs, those cultured 
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with phenytoin (30 µg/ml) or concurrently with phenytoin (30 µg/ml) and SB431542 (10 µM) 
were assessed for periostin levels using western blot at 24 h. While phenytoin (30 µg/ml) 
treatment alone increased periostin level in HGFs, SB431542 and phenytoin co-treatment did not 
alter periostin level compared to control.  
 
Increased p-SMAD2/3 in evident in PIGE tissues  
We qualitatively examined the patterns of phosphorylated-SMAD2/3 (p-SMAD2/3) level, in 
pathological samples isolated from patients with PIGE. Two specific patterns of p-SMAD 2/3 
were observed in the oral epithelium. Nuclear localization of p-SMAD3 through all layers of the 
epithelium was noted in samples with high inflammatory cell infiltration (Figure 3A, 68 yo). In 
samples with lower immune cell presence, p-SMAD3 localized mainly to the basal epithelial 
cells (Figure 3A, 56 yo). High immunoreactivity for p-SMAD2/3 was evident in the nuclei of 
gingival fibroblasts in all connective tissues obtained from PIGE samples (n = 11) but no 
labeling of p-SMAD2/3 was evident in healthy gingival tissues (n = 6) (Figure 3A). In samples 
with high immune cell infiltration, nuclear localization of p-SMAD3 was also evident in the 
nuclei of endothelial cells in the vasculature (Figure 3A, 68 yo). 
 
Phenytoin stimulates TGF-β signaling in HGFs in vitro 
TGF−β is a central player in fibrosis and is known to regulate periostin expression (Wen et al., 
2010; Zhou et al., 2010). We assessed whether phenytoin increases periostin protein levels 
through canonical TGF-β signaling in HGFs. To investigate the direct effect of phenytoin on 
TGF-β signaling in HGFs, we assessed SMAD3 activation changes in HGFs in vitro by 
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observing phosphorylated-SMAD3 (p-SMAD3) using western blot. Elevated p-SMAD3 was 
observed in HGFs treated with 15 and 30 µg/ml phenytoin, compared to control cells, at 30 
minutes post-treatment (Figure 3B). While phenytoin (30 µg/ml) treatment elevated p-SMAD3, 
SB431542 and PHE concurrent treatment attenuated p-SMAD3 increase. In fact, SB431542 and 
phenytoin co-treatment led to complete attenuation of p-SMAD3 compared to basal level 
(control).  
 
Myofibroblasts are not present in DIGE  
Prolonged persistence of myofibroblasts is a characteristic of fibrosis (Gabbiani., 2003). To 
evaluate whether myofibroblast differentiation is associated with DIGE, immunoreactivity for 
alpha-smooth	muscle	actin	(α-SMA) was assessed in histological gingival tissue sections from 
healthy subjects and patients clinically diagnosed with DIGE (Figure 4). In both groups of 
healthy and DIGE gingival tissues, α-SMA immunoreactivity was only evident in the 
vasculature.  
 
A subset of CD68 positive macrophages in PIGE tissues express TGF-β 
To assess whether any macrophages present in PIGE tissues have a pro-regenerative 
polarization, tissues were double stained for CD68 and TGF-β. In the healthy tissue, we did not 
observe CD68 stained cells (Figure 5A, B). In PIGE tissues, many CD68 positive cells were 
detected, with a subset of these cells labeling positive for TGF-β (Figure 5B, arrow).  
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RM3/1 positive macrophages are associated with PIGE 
As a subset of CD68 positive cells were associated with TGF-β expression, we labelled samples 
with antibodies to RM3/1, a marker of late stage inflammation and regenerative macrophages 
(Figure 6). Immunoreactivity for RM3/1 in healthy gingival samples was low, but in all PIGE 
samples, RM3/1 macrophages were present (Figure 6). The number of RM3/1 positive cells 
varied depending on the patient, but all PIGE samples were associated with regenerative 
macrophages.  
 
Discussion 
Current treatment options for the treatment of DIGE are largely limited to surgical removal of 
the overgrown tissue using gingival flap and scalpel gingivectomy. Such treatments persist due 
to our relatively poor understanding of the molecular mechanism underlying the disease (Brown 
et al., 1991). Although current surgical techniques are promising and often result in fairly good 
clinical outcomes, the recurrence rate of DIGE is high, around 34%, and the patients are then 
subjected to repeated surgical interventions (Ilgenli et al., 1999). Moreover, such surgical 
procedures are distressing and costly for patients, and whether these repeated insults to the tissue 
increase the rate of fibrosis is unknown. Discontinuation of the drug therapy can improve the 
condition but is rarely an option. Moreover, genetic, age, dose, duration of administration, and 
plaque are also reported to influence the development of DIGE. There have been several reports 
in particular highlighting an importance of plaque accumulation and gingival inflammation in 
DIGE. However, whether plaque is a significant factor in DIGE is controversial and reports are 
conflicting (Banthia et al., 2014; Sam and Sebastian., 2014). There is a fundamental lack of 
understanding of the molecular effects of these different drugs on gingival tissue. Development 
of novel preventative and therapeutic strategies to treat the disease are desperately needed, but a 
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clear understanding of the pathogenesis of DIGE, and the molecular mechanisms underlying the 
condition are required.  
Periostin, a pro-fibrotic matricellular protein, has been shown to be a significant player of 
collagen fibrillogenesis and synthesis in healing and fibrosis, often in collagen rich tissues 
(Norris et al., 2007; Norris et al., 2008a; Norris et al., 2008b; Zhou et al., 2010). Consistent to 
these previous findings, PIGE tissues also demonstrated elevated levels of periostin in the 
connective tissue. The elevated periostin level in PIGE may be the inducer of ECM accumulation 
that leads to fibrosis. Further studies need to be done to assess whether periostin is inducing 
fibrotic phenotypes in PIGE. Periostin was identified as a critical modulator of myofibroblast 
differentiation in the granulation tissue of healing skin, with expression peaking at day 7 (Elliott 
et al., 2012); periostin activates adhesive signaling through β1 integrins and focal adhesion 
kinase leading to myofibroblast differentiation. The prerequisite for myofibroblast differentiation 
is known to be a stiff matrix environment and adhesive signaling (Hinz., 2009). This suggests 
that there is likely a difference in the stiffness of healing skin and fibrotic lesions of the gingiva. 
This may explain the lack of myofibrobasts in PIGE regardless of elevated periostin. 
Furthermore, it demonstrates that periostin does not induce adhesive signaling in HGFs as seen 
in dermal fibroblasts (Elliott et al., 2012).  
As is the case in many types of fibrosis (Darby et al., 1990), the presence of 
myofibroblasts was described in gingival fibrosis, and indeed it was suggested to be central in 
drug-induced gingival fibromatosis (Yamasaki et al., 1987; Dill and Iacopino., 1997). However, 
recent research has shown an absence or low levels of myofibroblasts in fibrotic gingiva, 
idiopathic gingival fibromatosis (Sakamoto et al., 2002; Martelli et al., 2010), and DIGE 
resulting from administration of phenytoin (Sobral et al., 2010), nifedipine and amlopidine 
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(Pisoschi et al., 2014). These findings were not consistent with fibrotic features associated with 
gingival fibromatosis, and whether myofibroblast differentiation is present in DIGE is still 
controversial and needs to be further investigated, although our study suggests myofibroblasts 
are not present. What is evident is that whether myofibroblasts are present or not, higher collagen 
accumulation is consistently observed in fibrotic gingiva. Human gingival fibroblasts grown in 
nifedipine or phenytoin independently demonstrated a reduced phagocytic capacity in vitro 
(McCulloch and Knowles., 1993). Subsequently it has been demonstrated that reduced 
intracellular calcium levels are evident in the presence of the drugs (due to inhibited passage of 
calcium ions across membranes or release of calcium intracellular stores), which is likely to 
reduce the ability of the cells to limit phagocytosis (McCulloch., 2004).  
We respect to mechanisms of action of phenytoin in PIGE, it is clear that phenytoin acts 
through TGF-β pathways, resulting in p-SMAD2/3 nuclear translocation. We have previously 
shown that calcium-channel blocker nifedipine, activates TGF-β signaling to increase periostin 
in HGFs, although whether this is a direct effect of the drug has yet to be established (Kim et al., 
2013). Animal studies have demonstrated that TGF-β signaling plays a significant role in 
progression of cyclosporine and phenytoin induced gingival enlargement (Al-Hamilly et al., 
2016). The observation that both phenytoin and nifedipine can activate canonical TGF-β 
signaling in cultured cells suggests a common mechanism of action in gingival enlargement 
although the primary action of the drugs is different physiologically (phenytoin promotes sodium 
efflux Vs nifedipine which is a calcium antagonist). A recent study has suggested that phenytoin 
acts on HGFs through the non-selective cation channel transient receptor potential ankyrin 1 
(TRPA1) (Lopez-Gonzalez et al., 2017). Interestingly, a previous study demonstrated that 
TRPA1 is required for TGF-β signaling (Okada et al., 2014) and its deletion reduces corneal 
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fibrosis. Significantly, inhibition of TRPA1 suppressed inflammation and cellular processes 
associated with TGF-β signaling/fibrosis. Potential inhibition of TRPA1 as a mechanism to 
reduce DIGE is intriguing, although problems could exist for clinical utility based on its role as 
an analgesic (Gupta et al., 2016).  
A further finding of this study was that immunoreactivity for TGF-β co-localized with a 
subset of CD68 positive macrophages. It is therefore possible that TGF-β released by 
regenerative macrophages may also contribute to SMAD phosphorylation and periostin 
expression by gingival fibroblasts evident in PIGE tissues. Staining of the tissues for CD163 
(RM3/1), a marker of macrophages associated with the late inflammatory phase and tissue 
healing, found significant numbers of these cells present in all the PIGE tissues examined. 
Therefore, although it appears that phenytoin can activate TGF-β signaling directly through 
TRPA1, the presence of regenerative macrophages suggests that there is more than one 
mechanism leading to TGF-β signaling and progression of the fibrotic process in PIGE. TGF-β 
release from macrophages would bind directly to TGF-β receptors on HGFs, leading to SMAD 
phosphorylation. Therefore, inhibition of TRPA1 alone may not reduce fibrotic processes. 
In conclusion, we have demonstrated that PIGE is associated with TGF-β signaling and 
elevated levels of periostin protein. Moreover, our study shows that TGF-β signaling in PIGE 
could be attributed to direct activation of TGF-β likely through TRPA1 (Lopez-Gonzalez et al. 
2017) on gingival fibroblasts, as well as through macrophage release of TGF-β. We suggest that 
strategies to reduce DIGE will have to address different sources of TGF-β within the tissue and 
that one inhibitor alone may not be sufficient to prevent DIGE.  
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Figure legends 
Figure 1: Altered matrix production and tissue organization in gingival tissues from 
patients with PIGE.  
Collagen deposition in gingival tissues derived healthy subjects and DIGE patients. Masson’s 
trichrome stains collagen fibers in blue. Dense collagen accumulations are evident in the gingival 
tissues from patients experiencing DIGE. Lower magnification images are shown on the top 
panel whereas higher magnification images are shown on the low panel. Black arrows highlight 
areas of inflammatory cell infiltration.  
 
Figure 2: Periostin is upregulated in gingival connective tissues of phenytoin-induced 
gingival enlargement compared to healthy gingival tissue.  
A. Immuno-reactivity for periostin of gingival tissues from healthy subjects (n = 6), and 
phenytoin-induced gingival enlargement (n = 11) patients by immunohistochemistry. 
Representative images are shown. Sections were incubated with rabbit periostin primary 
antibody, which was detected with peroxidase conjugated secondary antibody and DAB. In 
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phenytoin-induced gingival enlargement tissues, periostin immuno-reactivity is greatly elevated 
in the connective tissue (Black arrows) compared to healthy tissue, where it localizes to the 
lamina propria (Black arrowheads). Primary delete (Negative) is shown inset B. PHE increases 
periostin levels via TGF-β signaling. Western blot showing periostin protein in cell lysates when 
HGFs were cultured with PHE (15 and 30 µg/ml) or without PHE (DMSO alone) for 1 day. 
HGFs treated with PHE (30 ug/ml) expressed a greater level of periostin. Western blot showing 
periostin is decreased in cell lysates when HGFs were cultured in combinations of PHE (30 
µg/ml) and SB431542 (10 µM) for 1 day. GAPDH was used as a loading control. 
 
Figure 3: Increased p-SMAD2/3 nuclear translocation is evident in PIGE. Immuno-
reactivity for phosphorylated-SMAD2/3 (p-SMAD2/3) gingival tissues from healthy subjects 
(N=6) and PIGF (N=11) patients using immunohistochemistry. Representative images are 
shown. Paraffin sections were incubated with a primary antibody and detected using peroxidase-
conjugated secondary antibody and DAB with haematoxylin counter-staining. Epithelium areas 
are shown on the top panel and the connective tissue areas are shown on the bottom panel. In 
some patients, pSMAD2/3 nuclear translocation was evident in the endothelial layer of blood 
vessels (White arrows). Black arrows highlight basal keratinocyte activation of pSMAD2/3. 
Primary delete (Negative) is shown inset B. Phenytoin induces canonical TGF-β signaling in 
HGFs. HGFs were cultured with phenytoin (15 µg/ml and 30 µg/ml) or without phenytoin 
(DMSO alone) for 30 minutes. SMAD3 activation was studied by assessing phosphorylated-
SMAD3 (p-SMAD3) by western blot. Phenytoin treated HGFs showed greater levels of p-
SMAD3. Inhibition of the TGF-β type I receptor attenuated p-SMAD3 in the presence of 
phenytoin. HGFs were cultured with without phenytoin (DMSO alone), phenytoin (30 µg/ml), or 
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both phenytoin (30 µg/mL) and SB431542 (10 μM) combined, and p-SMAD3 level was assessed 
using western blots in cell lysates. GAPDH was used as a loading control. 
 
Figure 4: Myofibroblasts are absent in the gingival tissues from patients with PIGE.  
A. Immunoreactivity for α-smooth muscle actin (α-SMA), the marker for myofibroblasts, in 
gingival tissues from healthy subjects (n = 6) and PIGE patients (n = 11). Sections were 
incubated with a primary antibody against α-SMA and detected using peroxidase-conjugate 
secondary antibody and DAB. All samples from both groups lacked α-SMA positive cells in the 
connective tissue, except in the smooth muscle of the blood vessel walls, which is the internal 
positive control for α-SMA. α-SMA-stained myofibroma tissue was used as the experimental 
positive control and primary delete (Negative) is shown inset. 
 
Figure 5. Co-localization of CD68 and TGF-β in PIGE tissues 
Fluorescent immunoreactivity for periostin in the gingival tissues from healthy subjects (n = 6) 
and PIGE patients and phenytoin (n = 11). Representative images are shown. Sections were 
incubated with primary antibodies against CD68 and TGF-β, which was detected using Cy5 (red) 
and FITC (green) conjugated secondary antibodies, respectively. Nuclei are stained with Hoechst 
3342 dye (blue). Elevated CD68 positive cells was observed in the connective tissues of PIGE 
and a subset of these cells were positive for TGF-β (white arrows). Primary delete (Negative) is 
shown inset.  
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Figure 6. RM3/1 positive macrophages are present in PIGE.  
Immunoreactivity for RΜ3/1 CD163), a marker of regenerative macrophages, in gingival tissues 
from healthy subjects (n = 6) and PIGE patients (n = 11). Sections were incubated with a primary 
antibody against RΜ3/1 and detected using peroxidase-conjugate secondary antibody and DAB. 
Elevated immunoreactivity for RM3/1 was observed in all PIGE samples. Primary delete 
(Negative) is shown inset.  
 
Table 1: Demographics of the patients with PIGE used in the study. 
Patient Gender Age Location 
PIGH1 Female 20 Left anterior maxillary gingiva 
PIGH2 Male 69 Interdental papilla 
PIGH3 Female 53 Left posterior mandibular gingiva 
PIGH4 Male 48 Alveolar mucosa 
PIGH5 Female 30 Maxillary and mandibular anterior 
gingiva 
PIGH6 Female 56 Maxillary anterior buccal gingiva 
PIGH7 Male 43 Left anterior mandibular gingiva 
PIGH8 Female 65 Right posterior mandibular gingiva 
PIGH9 Male 74 Left maxillary buccal alveolar 
mucosa 
PIGH10 Female 69 Maxillary gingiva 
PIGH11 Female 68 Mandibular gingiva 
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Patient Gender Age Location 
PIGH1 Female 20 Left anterior maxillary gingiva 
PIGH2 Male 69 Interdental papilla 
PIGH3 Female 53 Left posterior mandibular gingiva 
PIGH4 Male 48 Alveolar mucosa 
PIGH5 Female 30 Maxillary and mandibular anterior 
gingiva 
PIGH6 Female 56 Maxillary anterior buccal gingiva 
PIGH7 Male 43 Left anterior mandibular gingiva 
PIGHS Female 65 Right posterior mandibular gingiva 
PIGH9 Male 74 Left maxillary buccal alveolar 
mucosa 
PIGH10 Female 69 Maxillary gingiva 
PIGH11 Female 68 Mandibular gingiva 
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